Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

(2015) Mark Kriegsmann et al.   Oncotarget

Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer

(2014) K. Hashimoto et al.   ANNALS OF ONCOLOGY

Phosphatidylinositol 3-kinase (PI3KCA) Oncogene Mutation Analysis and Gene Expression Profiling in Primary Breast Cancer Patients

(2014) Mahesh Kandula et al.   Asian Pacific Journal of Cancer Prevention

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

(2014) Vandana G. Abramson et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations

(2014) V Secq et al.   BRITISH JOURNAL OF CANCER

Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes

(2014) L. S. Fink et al.   MOLECULAR CANCER THERAPEUTICS

Epidemiology of Breast Cancer

(2014) Kristen A. Ban et al.   Surgical Oncology Clinics of North America

The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine

(2013) Francine B. De Abreu et al.   AMERICAN JOURNAL OF PATHOLOGY

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

(2013) E. Tilch et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers

(2013) V. Gordon et al.   CLINICAL CANCER RESEARCH

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

(2013) Sherene Loi et al.   PLoS One

Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients

(2013) Yoonjung Kim et al.   PLoS One

Analysis of PIK3CA Mutations in Breast Cancer Subtypes

(2013) Ruza Arsenic et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

(2012) Tobias J. Grob et al.   BREAST CANCER RESEARCH AND TREATMENT

Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer

(2012) Ana M. Gonzalez-Angulo et al.   CANCER

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

(2012) F. Janku et al.   CANCER RESEARCH

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

(2012) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

(2011) Sandrine Boyault et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

(2010) Alfonso Sánchez-Muñoz et al.   BMC CANCER

Management of triple negative breast cancer

(2010) Catherine Oakman et al.   BREAST

Does the PI3K Pathway Play a Role in Basal Breast Cancer?

(2010) Stacy L. Moulder   Clinical Breast Cancer

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

High Sensitivity of Reverse-hybridization Methodology in the Detection of KRAS Mutations from Formalin-fixed Paraffin-embedded Colorectal Cancer Samples

(2010) Maria Rosaria De Miglio et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

(2008) Yuen-Liang Lai et al.   ANNALS OF SURGICAL ONCOLOGY

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Deregulation of the Akt Pathway in Human Cancer

(2008) Eriko Tokunaga et al.   CURRENT CANCER DRUG TARGETS

Refinement of breast cancer classification by molecular characterization of histological special types

(2008) B Weigelt et al.   JOURNAL OF PATHOLOGY